PF-05280014 Shows Equivalent ORR to Trastuzumab in HER2-positive Breast Cancer

Share this content:
Pfizer’s REFLECTIONS B3271002 study evaluating PF-05280014 as a potential biomarker to trastuzumab (Herceptin) met its primary endpoint.
Pfizer’s REFLECTIONS B3271002 study evaluating PF-05280014 as a potential biomarker to trastuzumab (Herceptin) met its primary endpoint.

Pfizer's REFLECTIONS B3271002 (ClinicalTrials.gov Identifier: NCT01989676) study evaluating PF-05280014 as a potential biomarker to trastuzumab (Herceptin) met its primary endpoint of objective response rate, according to a press release.1

In this phase 3 trial, researchers compared the safety and efficacy of PF-05280014 with paclitaxel against those of trastuzumab among patients with HER2-postive, metastatic breast cancer.

The study showed equivalence in objective response rate of PF-05280014 to Herceptin as first-line treatment in this setting.

RELATED: Fulvestrant Superior to Anastrozole for HR-positive Advanced Breast Cancer

PF-05280014 is a monoclonal antibody being tested as a potential biomarker for Herceptin, which is approved by the U.S. Food and Drug Administration for the treatment of HER2-positive breast and gastric cancers.

Reference

  1. Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab). Pfizer website. http://www.pfizer.com/news/press-release/press-release- detail/pfizer_announces_positive_top_line_results_from_the_pivotal_comparative_reflections_b3271002_study_for_pf_05280014_a_potential_biosimilar_to_herceptin_1_trastuzumab. Updated November 30, 2016. Accessed December 2, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters